SetPFPGroupVar.htm
   
SetPProProdListVar.htm

New User? Register Now

Returning User? Sign In

Benefits of registering


login.htm

Visit other Pfizer sites
Search Medical Responses
View an extensive list of Pfizer sites
ppn-vr-sso-links.htm

Share Your Feedback

Calendar

 

A Toll-Like Receptor 9 Agonist (TLR9)

  • Toll-like receptors (TLRs) are pattern-recognition receptors (PRRs). These receptors recognize molecules common to bacteria and viruses that are not present in mammalian cells1

  • Toll-like receptor 9 (TLR9) is expressed in 2 types of human immune cells, known as plasmacytoid dendritic cells (pDCs) and B cells2

  • TLR9 may be activated by DNA segments that contain unmethylated CpG motifs such as PF-3512676.3 PF-3512676 interacts with TLR9 and triggers its activation

Triggering both innate and adaptive immunity

Innate immunity

  • Within hours of activation by PF-3512676, pDCs secrete cytokines and chemokines able to mediate natural killer (NK) cells and T-cell responses3-5

Adaptive immunity

  • Within days of activation by PF-3512676, pDCs differentiate into antigen-presenting cells. Presentation of tumor antigen to T cells by mature pDCs stimulates the differentiation of these cells into cytotoxic T lymphocytes (CTLs)3,6,7
  • PF-3512676 is currently in clinical trials for:
    • Non-small cell lung cancer (NSCLC) - phase 2

PF-3512676 is an investigational compound.


Information in the Oncology Investigational Pipeline relates to therapies currently being researched.


References: 1. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987-995. 2. Krieg AM. Antitumor applications of stimulating tolllike receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep. 2004;6:88-95. 3. Krieg AM. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471-484. 4. Vollmer J. CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol. 2006;25:125-134. 5. Krieg AM, Efler SM, Wittpoth M, et al. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. Immunother. 2004;27:460-471. 6. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115:739-746. 7. Rothenfusser S, Hornung V, Ayyoub M, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood. 2004;103:2162-2169.

Clinical Trial Information


Clinical Trials Info

Visit our Clinical Trials section for a comprehensive database of Pfizer and non-Pfizer trials. go

Oncology Calendar


upcoming oncology conferences and events		 Learn about upcoming oncology conferences and events. go